AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
New HIV/AIDS research from W. Manosuthi et al outlined
July 13th, 2009
In this recent report, researchers in Nonthaburi, Thailand conducted a study "To our knowledge, to date, no prospective, randomized, clinical trial has compared standard doses of efavirenz- and nevirapine-based antiretroviral therapy among patients with concurrent human immunodeficiency virus type 1 (HIV-1) infection and tuberculosis (TB) who are receiving rifampicin. Rifampicin recipients with concurrent HIV-1 infection and TB were randomized to receive antiretroviral therapy that included either efavirenz ( 600 mg per day) or nevirapine ( 400 mg per day)." "Efavirenz and nevirapine concentrations at 12 h after dosing ( C-12) were monitored at weeks 6 and 12. CD4(+)...
Source: AIDS Weekly (2009-07-13)
|
